Castle Biosciences Announces Closing of Initial Public Offering & Full Exercise of Underwriters’ Option to Purchase Additio...
July 29 2019 - 5:42PM
Business Wire
Castle Biosciences, Inc. (Nasdaq: CSTL), announced today the
closing of its previously announced initial public offering of
4,600,000 shares of its common stock, which includes 600,000 shares
sold pursuant to the exercise in full by the underwriters of their
option to purchase additional shares, at a price to the public of
$16.00 per share. Including the option exercise, the gross proceeds
to Castle Biosciences from the offering, before deducting the
underwriting discounts and commissions and offering expenses, were
$73.6 million.
SVB Leerink and Baird acted as joint book-running managers for
the offering and as representatives of the underwriters. Canaccord
Genuity and BTIG acted as co-managers for the offering.
Registration statements relating to these securities have been
filed with the Securities and Exchange Commission and became
effective on July 24, 2019. The offering was made only by means of
a prospectus. Copies of the final prospectus related to the
offering may be obtained from: SVB Leerink LLC, Attention:
Syndicate Department, One Federal Street, 37th Floor, Boston, MA
02110, by telephone: (800) 808‐7525, ext. 6132, or by e‐mail:
syndicate@svbleerink.com; or Robert W. Baird & Co.
Incorporated, Attention: Syndicate Department, 777 East Wisconsin
Ave., Milwaukee, WI 53202, by telephone: (800) 792-2473, or by
email: syndicate@rwbaird.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Castle Biosciences
Castle Biosciences is a commercial-stage dermatological cancer
company focused on providing physicians and their patients with
personalized, clinically actionable genomic information to make
more accurate treatment decisions.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190729005756/en/
Castle Biosciences, Inc. Derek Maetzold, President and CEO
866-788-9007
Castle Biosciences (NASDAQ:CSTL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Castle Biosciences (NASDAQ:CSTL)
Historical Stock Chart
From Apr 2023 to Apr 2024